Thrombolytic utilization for ischemic stroke in US hospitals with neurology residency program

Neurology

Volumn 81, Issue 23, 2013, Pages 1986-1995

  Moradiya, Yogesh ^a,b,c   Crystal, Howard ^b   Valsamis, Helen ^b,c   Levine, Steven R ^b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c KINGS COUNTY HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFICACY; FEMALE; HOSPITAL; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUROLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; RESIDENCY EDUCATION; RETROSPECTIVE STUDY; STANDARD; STROKE PATIENT; TEACHING HOSPITAL; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALS; HUMANS; INTERNSHIP AND RESIDENCY; MALE; MIDDLE AGED; NEUROLOGY; RETROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; UNITED STATES;

EID: 84892429826     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000436946.08647.b5     Document Type: Article

References (40)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-1587
2. Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet 2012; 379:2352-2363
3. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329
4. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011;42:1952-1955
5. Prabhakaran S, McNulty M, O'Neill K, Ouyang B. Intravenous thrombolysis for stroke increases over time at primary stroke centers. Stroke 2012;43:875-877.
6. Kansara A, Chaturvedi S, Bhattacharya P. Thrombolysis and outcome of young stroke patients over the last decade: insights from the nationwide inpatient sample. J Stroke Cerebrovasc Dis 2012;22:799-804
7. Schumacher HC, Bateman BT, Boden-Albala B, et al. Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample 1999 to 2004. Ann Emerg Med 2007;50:99-107
8. Overview of the nationwide inpatient sample (NIS) [online]. Available at: www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed December 1, 2012
9. Human subject regulations decision charts [online]. Available at: http://www.hhs.gov/ohrp/policy/checklists/decisioncharts. html. Accessed December 1, 2012.
10. Goldstein LB. Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: effect of modifier codes. Stroke 1998;29:1602-1604.
11. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10. Stroke 2005;36:1776-1781.
12. Roumie CL, Mitchel E, Gideon PS, Varas-Lorenzo C, Castellsague J, Griffin MR. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf 2008;17:20-26
13. Williams GR. Incidence and characteristics of total stroke in the United States. BMC Neurol 2001;1:2
14. Dubinsky R, Lai SM. Mortality of stroke patients treated with thrombolysis: analysis of Nationwide Inpatient Sample. Neurology 2006;66:1742-1744
15. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39:924-928
16. Accredited programs and sponsoring institutions [online]. Available at: http://www.acgme.org/acgmeweb/acgmeweb/ tabid/172/GraduateMedicalEducation/ AccreditedProgramsand SponsorSearch.aspx. Accessed December 1, 2012
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383
18. Goldstein LB, Samsa GP, Matchar DB, Horner RD. Charlson Index comorbidity adjustment for ischemic stroke outcome studies. Stroke 2004;35:1941-1945
19. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics: 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245.
20. Petrea RE, Beiser AS, Seshadri S, Kelly-Hayes M, Kase CS, Wolf PA. Gender differences in stroke incidence and poststroke disability in the Framingham Heart Study. Stroke 2009;40:1032-1037.
21. HCUP comorbidity software [online]. Available at: http:// www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity. jsp. Accessed December 1, 2012.
22. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
23. Saposnik G, Baibergenova A, O'Donnell M, Hill MD, Kapral MK, Hachinski V. Hospital volume and stroke outcome: does it matter? Neurology 2007;69:1142-1151.
24. Joint Commission certified organizations [online]. Available at: http://www.qualitycheck.org/help-certified-orgs. aspx. Accessed December 1, 2012.
25. Houchens R, Elixhauser A. Final report on calculating nationwide inpatient sample (NIS) variances, 2001 [online]. Available at: http://www.hcup-us.ahrq.gov/reports/ methods/ CalculatingNISVariances200106092005.pdf. Accessed December 1, 2012.
26. Rost NS, Smith EE, Pervez MA, Mello P, Dreyer P, Schwamm LH. Predictors of increased intravenous tissue plasminogen activator use among hospitals participating in the Massachusetts primary stroke service program. Circ Cardiovasc Qual Outcomes 2012;5:314-320.
27. Nasr DM, Brinjikji W, Cloft HJ, Rabinstein AA. Racial and ethnic disparities in the use of intravenous recombinant tissue plasminogen activator and outcomes for acute ischemic stroke. J Stroke Cerebrovasc Dis 2013; 22:154-160.
28. Keyhani S, Arling G, Williams LS, et al. The use and misuse of thrombolytic therapy within the Veterans Health Administration. Med Care 2012;50:66-73.
29. Allen NB, Kaltenbach L, Goldstein LB, et al. Regional variation in recommended treatments for ischemic stroke and TIA: Get With the Guidelines-Stroke 2003-2010. Stroke 2012;43:1858-1864.
30. Kleindorfer D, Xu Y, Moomaw CJ, Khatri P, Adeoye O, Hornung R. US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke 2009;40: 3580-3584.
31. Lichtman JH, Watanabe E, Allen NB, Jones SB, Dostal J, Goldstein LB. Hospital arrival time and intravenous t-PA use in US academic medical centers, 2001-2004. Stroke 2009;40:3845-3850
32. Smaha LA. The American Heart Association Get With the Guidelines program. Am Heart J 2004;148:S46-S48
33. Mullen MT, Kasner SE, Kallan MJ, Kleindorfer DO, Albright KC, Carr BG. Joint Commission primary stroke centers utilize more rt-PA in the nationwide inpatient sample. J Am Heart Assoc 2013;2:e000071
34. Demaerschalk BM, Durocher DL. How diagnosisrelated group 559 will change the US Medicare cost reimbursement ratio for stroke centers. Stroke 2007;38: 1309-1312.
35. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945-2948
36. Frey JL, Jahnke HK, Goslar PW, Partovi S, Flaster MS. tPA by telephone: extending the benefits of a comprehensive stroke center. Neurology 2005;64:154-156.
37. Fonarow GC, Reeves MJ, Zhao X, et al. Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke. Circulation 2010;121:879-891
38. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005;43:480-485
39. Andrade SE, Harrold LR, Tjia J, et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf 2012;21(suppl 1):100-128.
40. Qureshi AI, Harris-Lane P, Siddiqi F, Kirmani JF. International Classification of Diseases and current procedural terminology codes underestimated thrombolytic use for ischemic stroke. J Clin Epidemiol 2006;59:856-858.